Form 4: Dexcom CFO Jereme Sylvain Reports Stock Transactions and RSU Grants

EVP and CFO of Dexcom, Jereme Sylvain, reports the acquisition and disposal of Dexcom common stock, including grants of restricted stock units (RSUs) and sales of shares on March 8th and 10th, 2025.

Summary

• Jereme M. Sylvain, EVP and Chief Financial Officer of Dexcom Inc., filed a Form 4 detailing changes in beneficial ownership.
• On March 8, 2025, Sylvain received two grants of restricted stock units (RSUs): 35,906 RSUs vesting in three equal annual installments and 22,798 RSUs vesting over a period ending March 8, 2027.
• On March 10, 2025, Sylvain sold 2,670 shares at an average price of $73.217, 3,203 shares at an average price of $74.0404, and 1,127 shares at an average price of $74.7023.
• Following these transactions, Sylvain beneficially owns 135,482 shares of Dexcom common stock, including 83,328 unvested RSUs.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting transactions. The stock sales could be seen as slightly negative, but the RSU grants are a positive sign of continued investment in the company's future.

Positives

• The grant of RSUs to the CFO aligns his interests with the long-term performance of the company.

Negatives

• The sale of shares by the CFO could be interpreted negatively by some investors, although it appears to be a small percentage of his total holdings.

Risks

• The vesting of RSUs is contingent and may not occur if Sylvain leaves the company before the vesting dates.

Industry Context

Insider transactions are common in publicly traded companies and are closely monitored by investors for signals about management's confidence in the company's future prospects. Form 4 filings are a routine part of regulatory compliance for company executives.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with shareholders, similar to practices at companies like Medtronic, Abbott, and Boston Scientific.
• The vesting schedules for RSUs are typical, with annual or semi-annual vesting over a period of several years, which is consistent with industry standards for retaining key personnel.

Stakeholder Impact

• Shareholders may react to the stock sales, but the overall impact is likely to be minimal given the relatively small number of shares sold.
• Employees may view the RSU grants as a positive sign of the company's commitment to its executives.

Key Dates